September 3, 2025 – VelaVigo (Shanghai) Limited (VelaVigo), a subsidiary of VelaVigo Cayman Limited and a biotech company with a robust discovery and development platform for multispecific antibodies and antibody-drug conjugates (ADCs), congratulates its partner Avenzo Therapeutics, Inc. (“Avenzo”) on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific ADC. This IND clearance follows the strategic collaboration established by the two companies on November 18, 2024.
Avenzo has exercised its exclusive option for AVZO-103 from VelaVigo, securing global (excluding Greater China) development, manufacturing, and commercialisation rights.
Dr. Jing Li, CEO of VelaVigo, commented, “We congratulate Avenzo on reaching this important milestone. AVZO-103 is a key outcome of our strategic collaboration and underscores our shared commitment to advancing innovative oncology therapies.”
Dr. Li added, “With two assets entering the clinic this year as we continue to build a robust pipeline of innovative molecules, we demonstrate our ability to translate cutting-edge science into impactful clinical-stage programs, driven by both strategic partnerships and internal innovation. We look forward to the great success of AVZO-103 to benefit more patients.
